Monday, July 6, 2009

Hyperion Therapeutics Raises $60M

South San Francisco-based Hyperion Therapeutics, which is developing pharmaceuticals for the gastroenterology and hepatology areas, announced today that it has raised $60M in a Series C financing round. The round was led by Bay City Capital and Panorama Capital, and also included Highland Capital Partners, NEA, and Sofinnova Ventures. Hyperion Therapeutics said the funding will go towards a Phase III clinical program for treating urea cycle disorders, and a Phase II study for treating low grade hepatic encephalopathy. Bay City's H. Daniel Perez, and Panorama's Guarav Aggrawal join the board as part of the funding. More information »